Journal article

Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target

Fortunato Morabito, Massimo Gentile, John F Seymour, Aaron Polliack

Leukemia & Lymphoma | TAYLOR & FRANCIS LTD | Published : 2015

DOI: 10.3109/10428194.2015.1061193

Citation metrics

16Web of Science
17Scopus

Keywords

Antibodies, Monoclonal, Humanized
Science & Technology
Idelalisib
Targeted Therapy
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma
Ibrutinib
Chronic Lymphocytic Leukemia
Protein-Tyrosine Kinases
Molecular Targeted Therapy
Agammaglobulinaemia Tyrosine Kinase
Disease
Hematology
Obinutuzumab
Kinase Inhibitor Ibrutinib
Pyrazoles
Protein Kinase Inhibitors
Anti-Cd20 Antibody
Antigens, Cd20
Initial Therapy
Humans
Cll
Cal-101
Open-Label
Clinical Trials As Topic
Class Ia Phosphatidylinositol 3-Kinase
Pyrimidines
Quinazolinones
Phosphoinositide-3 Kinase Inhibitors
Oncology
Rituximab
Mechanisms
Antineoplastic Combined Chemotherapy Protocols
Life Sciences & Biomedicine
Treatment Outcome
Purines